Uncategorized

The drug trastuzumab emtansine (Kadcyla) will soon be routinely available for patients in England with an advanced type of breast cancer. NHS England has announced that a discounted deal has been agreed with the manufacturer Roche, which has been backed by the National Institute for Health and Care Excellence (NICE) who previously judged the drug as too expensive. Professor Arnie Purushotham, Cancer Research UK’s senior clinical adviser, said that he was delighted to see the three organisations working together to make it available for patients. Research has shown that the drug can benefit women with a type of breast cancer called HER2-positive that has spread to other parts of the body, can’t be surgically removed and has stopped responding to other treatments. 

See original article at: https://www.cancerresearchuk.org/about-us/cancer-news/news-report/2017-06-16-breast-cancer-drug-approved-for-nhs-england